Browsing Tag
Novartis AG
16 posts
Novartis Fabhalta wins first FDA traditional approval to slow IgAN kidney decline
Novartis has won FDA traditional approval for Fabhalta to slow kidney function decline in adults with primary IgA nephropathy, upgrading a 2024 accelerated label into the first full complement-inhibitor claim on eGFR. The decision moves Novartis ahead of Vera Therapeutics' Trutakna, which received only accelerated approval on 7 July, and lands one day before the Novartis Q2 2026 earnings release. The commercial question is whether Fabhalta's oral, disease-modifying label can convert into a durable IgAN franchise against a widening field of complement, endothelin and B-cell targeted therapies.
Vera Therapeutics wins FDA approval for Trutakna as VERA stock jumps
Vera Therapeutics wins FDA approval for Trutakna as VERA stock jumps. Read how launch execution, pricing and full approval risks shape the next phase.
Novartis agrees $1.5bn Myricx Bio deal as ADC platform race intensifies
Novartis will pay $1.1 billion upfront for preclinical biotech Myricx Bio. Read why its novel ADC payload could reshape oncology strategy and NVS sentiment.
Ipsen to buy Kartos Therapeutics for up to $1.75bn as IPN nears 52-week high
Ipsen is buying Kartos for up to $1.75 billion. Read how navtemadlin could reshape its oncology pipeline, earnings outlook and IPN valuation after the deal.
Nuvectis (NVCT) licenses two Haisco drugs as $1.46bn deal transforms its pipeline
Nuvectis licenses two Haisco drugs in a deal worth up to $1.46 billion. Find out how financing risk could reshape NVCT’s pipeline and investor outlook next.
Why Novartis’ $12bn Avidity bet suddenly looks more interesting after new del-brax data
Find out how Novartis AG’s del-brax data could strengthen its $12bn Avidity Biosciences bet and rare muscle disease strategy.
Atrium Therapeutics (Nasdaq: RNA) Q1 results show cash runway and clinical urgency behind precision cardiology bet
Atrium has cash and RNA ambition. The harder test is whether heart-targeted delivery can turn rare cardiomyopathy science into clinical proof.
How pediatric biologic approvals are transforming hidradenitis suppurativa treatment
Novartis AG expands Cosentyx approval to adolescents with hidradenitis suppurativa. Discover what this means for dermatology biologics and investors.
Can RNA medicines really reach the heart? Atrium Therapeutics (Nasdaq: RNA) is putting $270m on the line
Atrium Therapeutics launches with $270 million to advance RNA medicines for rare genetic cardiomyopathies. Find out why investors are watching closely.
Dr. Reddy’s (NSE: DRREDDY) signals dual-track U.S. growth strategy with abatacept biosimilar BLA acceptance and OTC eye-care expansion
Discover how Dr. Reddy’s FDA-accepted abatacept biosimilar and OTC eye-care launch are reshaping its U.S. growth and investor outlook.